Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
